Newpath Partners
About
Newpath Partners Newpath Partners was founded in 2018 by Tom Cahill, an MD/PhD physician-scientist who moved into investing. Fund II closed at $350M in December 2021 with a mandate to create life sciences companies, not just fund them. The firm specializes in breakthrough biology platforms. gene editing and regenerative medicine in particular. The portfolio includes 13 companies, with 2 IPOs and 3 acquisitions (Neumora, Metsera, YourBio). The gene editing work is especially interesting: Prime M
Industries
Stage focus
SeedSeries A
Geography
US
Notable investments
- Prime Medicine
- Chroma Medicine
- Myeloid Therapeutics
- Kojin Therapeutics
- Exo Therapeutics
Raising from Newpath Partners?
I've worked with founders across the industrial stack. If Newpath Partners is on your list, I can help you map the introduction path, sharpen the narrative, and run a tight process.
Talk to Dan